Recombinant Human Granulocyte Macrophage Colony Stimulating Factor

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (rHu GM-CSF) is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Akron Biotech
 
Recombinant Human Granulocyte Macrophage Colony StimulatingFactor (rHu GM-CSF) is produced in response to a number of inflammatorymediators by mesenchymal cells present in the hemopoietic environment and atperipheral sites of inflammation. GM-CSF is able to stimulate the production ofneutrophilic granulocytes, macrophages, and mixed granulocyte-macrophagecolonies from bone marrow cells and can stimulate the formation of eosinophilcolonies from fetal liver progenitor cells. GM-CSF can also stimulate somefunctional activities in mature granulocytes and macrophages. rHu GM-CSFreceptors show significant homologies with other receptors for hematopoieticgrowth factors, including IL2-beta, IL-3, IL-6, IL-7, EPO and the Prolactinreceptors. rHu GM-CSF produced in E. coli is a single, non-glycosylated,polypeptide chain that contains 127 amino acids and has a molecular mass of14.48 kDa. The product is very stable for up to three years from manufacturingdate, when stored lyophilized at -20° C.
 
 
Akron Biotech
(561) 750-6120
 www.akronbiotech.com

 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue